Quercetin Phytosome® as a potential candidate for managing COVID-19
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
When looking for new antiviral compounds aimed to counteract the COVID-19, a disease caused by the recently identified novel Coronavirus (SARS-CoV-2), the knowledge of the main viral proteins is fundamental. The major druggable targets of SARS-CoV-2 include 3-chymotrypsin-like protease (3CLpro), papain-like protease (PLpro), RNA-dependent RNA polymerase, and spike (S) protein. Molecular docking studies have highlighted that quercetin, a natural polyphenol belonging to the flavonol class, inhibits 3CLpro, PLpro and S proteins. Biophysical technics have then very recently confirmed that quercetin is reasonably a potent inhibitor of 3CLpro. The likely antiviral properties of quercetin are anyway challenged by its very poor oral bioavailability profile and any attempt to overcome this limit should be welcome. A phospholipid delivery form of quercetin (Quercetin Phytosome®) has been recently tested in humans to evaluate a possible improvement in oral bioavailability. After hydrolysis of the conjugated form (mainly glucuronide) of quercetin found in human plasma, the pharmacokinetics results have demonstrated an increased bioavailability rate by about 20-fold for total quercetin. It has been also observed that the presence of specific glucuronidase could yield free systemic quercetin in human body. Taking also into considerations its anti-inflammatory and thrombin-inhibitory actions, a bioavailable form of quercetin, like Quercetin Phytosome®, should be considered a possible candidate to clinically face COVID-19.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir
Yin, W., Mao, C., Luan, X., Shen, D.-D., Shen, Q., Su, H., Wang, X., Zhou, F., Zhao, W., Gao, M., et al. (2020) · Science · doi:10.1126/science.abc1560 · Cited by 1,219
Accurate calculation of the absolute free energy of binding for drug molecules
Aldeghi, M., Heifetz, A., Bodkin, M. J., Knapp, S., & Biggin, P. C. (2016) · Chemical Science · doi:10.1039/c5sc02678d · Cited by 347
Cheng, S.-C., Huang, W.-C., S. Pang, J.-H., Wu, Y.-H., & Cheng, C.-Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20122957 · Cited by 235
Research works printed but not linked: 36
- Kannan S, 2020, COVID-19 (Novel Coronavirus 2019) - recent trends, Eur Rev Med Pharmacol Sci, 24, 2006
- 10.4103/0973-7847.194044 · DOI · Paper page
- 10.1016/j.jcrc.2020.03.005 · DOI · Paper page
- 10.5582/bst.2020.03072 · doi:10.5582/bst.2020.03072
- 10.1002/jmv.25729 · DOI · Paper page
- Khamitov RA, 2008, [Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures], Vopr Virusol, 53, 9
- 10.5582/bst.2020.01020 · DOI · Paper page
- 10.1016/j.ijsu.2020.03.036 · doi:10.1016/j.ijsu.2020.03.036
- 10.1016/j.apsb.2020.02.008 · DOI · Paper page
- 10.1002/jmv.25761 · DOI · Paper page
- 10.1016/j.joim.2020.02.005 · DOI · Paper page
- 10.1038/nprot.2016.051 · DOI · Paper page
- 10.1021/acs.jcim.7b00341 · DOI · Paper page
- 10.1016/j.ctim.2019.102294 · DOI · Paper page
- Smith M, 2020, Repurposing therapeutics for COVID-19: supercomputer-based docking to the SARS-CoV-2 viral spike protein and viral spike protein-human ACE2 interface, ChemRxiv, ahead of print
- 10.1016/j.bcp.2020.114123 · DOI
- Pandey P, 2020, Targeting SARS-CoV-2 spike protein of COVID-19 with naturally occurring phytochemicals: an in silico study for drug development, J Biomol Struct Dyn, 1, 10.1080/07391102.2020.1796811 · DOI · Paper page
- Khaerunnisa S, 2020, Potential inhibitor of COVID-19 main protease (Mpro) from several medicinal plant compounds by molecular docking study, Preprints, ahead of print
- 10.1016/j.ijbiomac.2020.07.235 · DOI · Paper page
- 10.1016/j.ijpharm.2010.11.009 · DOI · Paper page
- 10.1016/j.tifs.2016.07.004 · DOI · Paper page
- 10.1007/s13318-018-0517-3 · DOI · Paper page
- 10.1079/BJN20061809 · DOI · Paper page
- 10.1093/ajcn/79.5.727 · DOI · Paper page
- 10.3390/nu9020111 · DOI
- 10.1007/s00394-003-0397-3 · DOI · Paper page
- 10.1371/journal.pone.0032673 · DOI
- Shimoi K, 2001, Deglucuronidation of a flavonoid, luteolin monoglucuronide, during inflammation, Drug Metab Dispos, 29, 1521
- 10.1016/j.abb.2008.03.004 · DOI · Paper page
- 10.2174/138161210790112674 · doi:10.2174/138161210790112674
- 10.1016/S0140-6736(20)30937-5 · DOI · Paper page
- 10.1128/AAC.00530-20 · DOI
- 10.1016/j.thromres.2010.08.006 · doi:10.1016/j.thromres.2010.08.006
- 10.1016/j.phrs.2010.05.001 · DOI · Paper page
- 10.1186/s13020-020-00317-x · DOI · Paper page
- 10.1002/ptr.6887 · DOI · Paper page
Cited by
Di Pierro, F., Derosa, G., Maffioli, P., Bertuccioli, A., Togni, S., Riva, A., Allegrini, P., Khan, A., Khan, S., Khan, B. A., et al. (2021) · International Journal of General Medicine · doi:10.2147/ijgm.s318720 · Cited by 182
Self-citationDi Pierro, F., Iqtadar, S., Khan, A., Ullah Mumtaz, S., Masud Chaudhry, M., Bertuccioli, A., Derosa, G., Maffioli, P., Togni, S., Riva, A., et al. (2021) · International Journal of General Medicine · doi:10.2147/ijgm.s318949 · Cited by 180
“There is some recent evidence of the anti-coronavirus activities of this compound, including against SARS-CoV-2 main proteases and S-protein.(25) Its assumed ability to inhibit coronavirus and its well-described anti-inflammatory role make quercetin a possible new candidate for outpatients’ treatment of COVID-19.”
BackgroundSelf-citationZeng, J., Bao, T., Yang, K., Zhu, X., Wang, S., Xiang, W., Ge, A., Zeng, L., & Ge, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1047550 · Cited by 175
COVID-19 and cellular senescence
Schmitt, C. A., Tchkonia, T., Niedernhofer, L. J., Robbins, P. D., Kirkland, J. L., & Lee, S. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00785-2 · Cited by 153
The Interaction of Viruses with the Cellular Senescence Response
Seoane, R., Vidal, S., Bouzaher, Y. H., El Motiam, A., & Rivas, C. (2020) · Biology · doi:10.3390/biology9120455 · Cited by 49
Metadata
- Authors
- DI PIERRO, F., KHAN, A., BERTUCCIOLI, A., MAFFIOLI, P., DEROSA, G., KHAN, S., KHAN, B. A., NIGAR, R., UJJAN, I., & DEVRAJANI, B. R.
- Venue
- Minerva Gastroenterology
- Publisher
- Edizioni Minerva Medica
- Published
- 2021-05
- Volume
- 67
- Issue
- 2
- Pages
- 190-195
- ISSN
- 0026-4776 (ISSN-L)
- 2724-5985
- 2724-5365
- OpenAlex
- W3091043182
- Cited by
- 41
- References
- 3
- FWCI
- 4.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Quercetin Phytosome® as a potential candidate for managing COVID-19. https://app.cochat.ai/papers/10.23736/s2724-5985.20.02771-3
- The paper
- DI PIERRO, F., KHAN, A., BERTUCCIOLI, A., MAFFIOLI, P., DEROSA, G., KHAN, S., KHAN, B. A., NIGAR, R., UJJAN, I., & DEVRAJANI, B. R. (2021). Quercetin Phytosome® as a potential candidate for managing COVID-19. Minerva Gastroenterology. https://doi.org/10.23736/s2724-5985.20.02771-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.